Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

HCV Direct Acting Antiviral Market by  Product Type (HCV Antibody, HCV Viral Load, HCV Genotyping), by Drug Class (NS3/4A Protease Inhibitors, NS5A Polymerase Inhibitors, NS5B Polymerase Inhibitors, Combination Drugs) and by Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032

A13196

Pages: NA

Charts: NA

Tables: NA

HCV Direct Acting Antiviral Market Overview 2030

Hepatitis C is a viral infection that causes inflammation of the liver, which can lead to severe liver damage. Infections caused by the blood-borne virus hepatitis C virus (HCV) are spread through contaminated blood. There is improvement in the management of patients suffering from HCA infections and the patients can be easily treated with the use of oral medication. This treatment will last for two to six months, depending on the patient’s improvement and the recommendations of the healthcare provider. Hepatitis C is one of the main causes of liver cancer.

COVID-19 Impact Analysis             

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the HCV direct acting antiviral market.

Top Impacting Factors

  • Rise in cases of liver diseases, increase in incidence of hospital acquired infection across the globe, surge in prevalence of infectious diseases, rise in demand of early diagnosis of chronic infectious diseases, surge in geriatric population, and lack of sanitization practices are the key factors that drive the growth of the HCV direct acting antiviral market.
  • In addition, rise in demand of advance healthcare services, increase in investments on healthcare sector, surge in adoption of unhealthy lifestyle, increase in usage of personalized medication procedures, rise in usage of oral antiviral medications, and increase in usage of minimally invasive hepatitis C treatment procedures are some factors that fuel the growth of the HCV direct acting antiviral market.
  • However, severe adverse effects related use of anti-viral drugs hinder the growth of the market.
  • Contrarily, government initiatives to spread awareness regarding treatment of hepatitis C treatment and fast track regulatory approvals for novel drugs are expected to offer lucrative opportunities for the expansion of the HCV direct acting antiviral market.

Market Trends

New Product Launches to Flourish the Market

In 2020, Gilead announced launch of Hepatitis C antiviral VOSEVI drug in China. This drug is a direct acting antiviral drug which can be used in treatment of mild to severe hepatitis C infection.

In 2019, AbbVie announced approval of U.S. Food and Drug Administration for launch of Mavyret medication. This product is an antiviral drug which can be used in treatment of all type of genetoypes of Hepatitis C in pediatric patients.

Key Benefits of the Report

  • This study presents the analytical depiction of HCV direct acting antiviral market industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the HCV direct acting antiviral market share.
  • The current market is quantitatively analyzed to highlight the HCV direct acting antiviral market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the HCV Direct Acting Antiviral Market Report    

  • Which are the leading players active in the HCV direct acting antiviral market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What is "HCV direct acting antiviral"?
  • What is "HCV direct acting antiviral" market prediction in the future?
  • Who are the leading global players in the "HCV direct acting antiviral" market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "HCV direct acting antiviral" market report?

 Key Market Segments

  • By  Product Type
    • HCV Antibody
    • HCV Viral Load
    • HCV Genotyping
  • By Drug Class
    • NS3/4A Protease Inhibitors
    • NS5A Polymerase Inhibitors
    • NS5B Polymerase Inhibitors
    • Combination Drugs
  • By Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Gilead Sciences.
  • Bristol Myers Squibb
  • F. Hoffmann-La Roche
  • AbbVie
  • Genentech
  • Johnson and Johnson Services, Inc.
  • Vertex
  • Merck & Co.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: HCV DIRECT ACTING ANTIVIRAL MARKET, BY  PRODUCT TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By  product Type

    • 4.2. HCV Antibody

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. HCV Viral Load

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. HCV Genotyping

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: HCV DIRECT ACTING ANTIVIRAL MARKET, BY DRUG CLASS

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Drug Class

    • 5.2. NS3/4A Protease Inhibitors

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. NS5A Polymerase Inhibitors

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. NS5B Polymerase Inhibitors

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Combination Drugs

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

  • CHAPTER 6: HCV DIRECT ACTING ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Distribution Channel

    • 6.2. Hospital Pharmacy

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Online Pharmacy

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Retail Pharmacy

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: HCV DIRECT ACTING ANTIVIRAL MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By  product Type

      • 7.2.3. Market Size and Forecast, By Drug Class

      • 7.2.4. Market Size and Forecast, By Distribution Channel

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Hcv Direct Acting Antiviral Market

        • 7.2.6.1. Market Size and Forecast, By  product Type
        • 7.2.6.2. Market Size and Forecast, By Drug Class
        • 7.2.6.3. Market Size and Forecast, By Distribution Channel

      • 7.2.7. Canada Hcv Direct Acting Antiviral Market

        • 7.2.7.1. Market Size and Forecast, By  product Type
        • 7.2.7.2. Market Size and Forecast, By Drug Class
        • 7.2.7.3. Market Size and Forecast, By Distribution Channel

      • 7.2.8. Mexico Hcv Direct Acting Antiviral Market

        • 7.2.8.1. Market Size and Forecast, By  product Type
        • 7.2.8.2. Market Size and Forecast, By Drug Class
        • 7.2.8.3. Market Size and Forecast, By Distribution Channel

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By  product Type

      • 7.3.3. Market Size and Forecast, By Drug Class

      • 7.3.4. Market Size and Forecast, By Distribution Channel

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Hcv Direct Acting Antiviral Market

        • 7.3.6.1. Market Size and Forecast, By  product Type
        • 7.3.6.2. Market Size and Forecast, By Drug Class
        • 7.3.6.3. Market Size and Forecast, By Distribution Channel

      • 7.3.7. Germany Hcv Direct Acting Antiviral Market

        • 7.3.7.1. Market Size and Forecast, By  product Type
        • 7.3.7.2. Market Size and Forecast, By Drug Class
        • 7.3.7.3. Market Size and Forecast, By Distribution Channel

      • 7.3.8. Italy Hcv Direct Acting Antiviral Market

        • 7.3.8.1. Market Size and Forecast, By  product Type
        • 7.3.8.2. Market Size and Forecast, By Drug Class
        • 7.3.8.3. Market Size and Forecast, By Distribution Channel

      • 7.3.9. Spain Hcv Direct Acting Antiviral Market

        • 7.3.9.1. Market Size and Forecast, By  product Type
        • 7.3.9.2. Market Size and Forecast, By Drug Class
        • 7.3.9.3. Market Size and Forecast, By Distribution Channel

      • 7.3.10. UK Hcv Direct Acting Antiviral Market

        • 7.3.10.1. Market Size and Forecast, By  product Type
        • 7.3.10.2. Market Size and Forecast, By Drug Class
        • 7.3.10.3. Market Size and Forecast, By Distribution Channel

      • 7.3.11. Russia Hcv Direct Acting Antiviral Market

        • 7.3.11.1. Market Size and Forecast, By  product Type
        • 7.3.11.2. Market Size and Forecast, By Drug Class
        • 7.3.11.3. Market Size and Forecast, By Distribution Channel

      • 7.3.12. Rest Of Europe Hcv Direct Acting Antiviral Market

        • 7.3.12.1. Market Size and Forecast, By  product Type
        • 7.3.12.2. Market Size and Forecast, By Drug Class
        • 7.3.12.3. Market Size and Forecast, By Distribution Channel

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By  product Type

      • 7.4.3. Market Size and Forecast, By Drug Class

      • 7.4.4. Market Size and Forecast, By Distribution Channel

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Hcv Direct Acting Antiviral Market

        • 7.4.6.1. Market Size and Forecast, By  product Type
        • 7.4.6.2. Market Size and Forecast, By Drug Class
        • 7.4.6.3. Market Size and Forecast, By Distribution Channel

      • 7.4.7. Japan Hcv Direct Acting Antiviral Market

        • 7.4.7.1. Market Size and Forecast, By  product Type
        • 7.4.7.2. Market Size and Forecast, By Drug Class
        • 7.4.7.3. Market Size and Forecast, By Distribution Channel

      • 7.4.8. India Hcv Direct Acting Antiviral Market

        • 7.4.8.1. Market Size and Forecast, By  product Type
        • 7.4.8.2. Market Size and Forecast, By Drug Class
        • 7.4.8.3. Market Size and Forecast, By Distribution Channel

      • 7.4.9. South Korea Hcv Direct Acting Antiviral Market

        • 7.4.9.1. Market Size and Forecast, By  product Type
        • 7.4.9.2. Market Size and Forecast, By Drug Class
        • 7.4.9.3. Market Size and Forecast, By Distribution Channel

      • 7.4.10. Australia Hcv Direct Acting Antiviral Market

        • 7.4.10.1. Market Size and Forecast, By  product Type
        • 7.4.10.2. Market Size and Forecast, By Drug Class
        • 7.4.10.3. Market Size and Forecast, By Distribution Channel

      • 7.4.11. Thailand Hcv Direct Acting Antiviral Market

        • 7.4.11.1. Market Size and Forecast, By  product Type
        • 7.4.11.2. Market Size and Forecast, By Drug Class
        • 7.4.11.3. Market Size and Forecast, By Distribution Channel

      • 7.4.12. Malaysia Hcv Direct Acting Antiviral Market

        • 7.4.12.1. Market Size and Forecast, By  product Type
        • 7.4.12.2. Market Size and Forecast, By Drug Class
        • 7.4.12.3. Market Size and Forecast, By Distribution Channel

      • 7.4.13. Indonesia Hcv Direct Acting Antiviral Market

        • 7.4.13.1. Market Size and Forecast, By  product Type
        • 7.4.13.2. Market Size and Forecast, By Drug Class
        • 7.4.13.3. Market Size and Forecast, By Distribution Channel

      • 7.4.14. Rest of Asia Pacific Hcv Direct Acting Antiviral Market

        • 7.4.14.1. Market Size and Forecast, By  product Type
        • 7.4.14.2. Market Size and Forecast, By Drug Class
        • 7.4.14.3. Market Size and Forecast, By Distribution Channel

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By  product Type

      • 7.5.3. Market Size and Forecast, By Drug Class

      • 7.5.4. Market Size and Forecast, By Distribution Channel

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Hcv Direct Acting Antiviral Market

        • 7.5.6.1. Market Size and Forecast, By  product Type
        • 7.5.6.2. Market Size and Forecast, By Drug Class
        • 7.5.6.3. Market Size and Forecast, By Distribution Channel

      • 7.5.7. South Africa Hcv Direct Acting Antiviral Market

        • 7.5.7.1. Market Size and Forecast, By  product Type
        • 7.5.7.2. Market Size and Forecast, By Drug Class
        • 7.5.7.3. Market Size and Forecast, By Distribution Channel

      • 7.5.8. Saudi Arabia Hcv Direct Acting Antiviral Market

        • 7.5.8.1. Market Size and Forecast, By  product Type
        • 7.5.8.2. Market Size and Forecast, By Drug Class
        • 7.5.8.3. Market Size and Forecast, By Distribution Channel

      • 7.5.9. UAE Hcv Direct Acting Antiviral Market

        • 7.5.9.1. Market Size and Forecast, By  product Type
        • 7.5.9.2. Market Size and Forecast, By Drug Class
        • 7.5.9.3. Market Size and Forecast, By Distribution Channel

      • 7.5.10. Argentina Hcv Direct Acting Antiviral Market

        • 7.5.10.1. Market Size and Forecast, By  product Type
        • 7.5.10.2. Market Size and Forecast, By Drug Class
        • 7.5.10.3. Market Size and Forecast, By Distribution Channel

      • 7.5.11. Rest of LAMEA Hcv Direct Acting Antiviral Market

        • 7.5.11.1. Market Size and Forecast, By  product Type
        • 7.5.11.2. Market Size and Forecast, By Drug Class
        • 7.5.11.3. Market Size and Forecast, By Distribution Channel

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Merck And Co.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Genentech

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Vertex

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Johnson And Johnson Services, Inc.

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. F. Hoffmann-La Roche

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Bristol Myers Squibb

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. AbbVie

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Gilead Sciences.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL HCV DIRECT ACTING ANTIVIRAL MARKET, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL HCV DIRECT ACTING ANTIVIRAL MARKET FOR HCV ANTIBODY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL HCV DIRECT ACTING ANTIVIRAL MARKET FOR HCV VIRAL LOAD, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL HCV DIRECT ACTING ANTIVIRAL MARKET FOR HCV GENOTYPING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL HCV DIRECT ACTING ANTIVIRAL MARKET, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL HCV DIRECT ACTING ANTIVIRAL MARKET FOR NS3/4A PROTEASE INHIBITORS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL HCV DIRECT ACTING ANTIVIRAL MARKET FOR NS5A POLYMERASE INHIBITORS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL HCV DIRECT ACTING ANTIVIRAL MARKET FOR NS5B POLYMERASE INHIBITORS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL HCV DIRECT ACTING ANTIVIRAL MARKET FOR COMBINATION DRUGS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL HCV DIRECT ACTING ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL HCV DIRECT ACTING ANTIVIRAL MARKET FOR HOSPITAL PHARMACY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL HCV DIRECT ACTING ANTIVIRAL MARKET FOR ONLINE PHARMACY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL HCV DIRECT ACTING ANTIVIRAL MARKET FOR RETAIL PHARMACY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL HCV DIRECT ACTING ANTIVIRAL MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. NORTH AMERICA HCV DIRECT ACTING ANTIVIRAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. NORTH AMERICA HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 17. NORTH AMERICA HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 18. NORTH AMERICA HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 19. U.S. HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 20. U.S. HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 21. U.S. HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 22. CANADA HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 23. CANADA HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 24. CANADA HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 25. MEXICO HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 26. MEXICO HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 27. MEXICO HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 28. EUROPE HCV DIRECT ACTING ANTIVIRAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 29. EUROPE HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 30. EUROPE HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 31. EUROPE HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 32. FRANCE HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 33. FRANCE HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 34. FRANCE HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 35. GERMANY HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 36. GERMANY HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 37. GERMANY HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 38. ITALY HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 39. ITALY HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 40. ITALY HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 41. SPAIN HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 42. SPAIN HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 43. SPAIN HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 44. UK HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 45. UK HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 46. UK HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 47. RUSSIA HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 48. RUSSIA HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 49. RUSSIA HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 50. REST OF EUROPE HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 51. REST OF EUROPE HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 52. REST OF EUROPE HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 53. ASIA-PACIFIC HCV DIRECT ACTING ANTIVIRAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 54. ASIA-PACIFIC HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 55. ASIA-PACIFIC HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 56. ASIA-PACIFIC HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 57. CHINA HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 58. CHINA HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 59. CHINA HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 60. JAPAN HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 61. JAPAN HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 62. JAPAN HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 63. INDIA HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 64. INDIA HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 65. INDIA HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 66. SOUTH KOREA HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 67. SOUTH KOREA HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 68. SOUTH KOREA HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 69. AUSTRALIA HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 70. AUSTRALIA HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 71. AUSTRALIA HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 72. THAILAND HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 73. THAILAND HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 74. THAILAND HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 75. MALAYSIA HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 76. MALAYSIA HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 77. MALAYSIA HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 78. INDONESIA HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 79. INDONESIA HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 80. INDONESIA HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 81. REST OF ASIA PACIFIC HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 84. LAMEA HCV DIRECT ACTING ANTIVIRAL, BY REGION, 2025-2033 ($MILLION)
  • TABLE 85. LAMEA HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 86. LAMEA HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 87. LAMEA HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 88. BRAZIL HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 89. BRAZIL HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 90. BRAZIL HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 91. SOUTH AFRICA HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 92. SOUTH AFRICA HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 93. SOUTH AFRICA HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 94. SAUDI ARABIA HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 95. SAUDI ARABIA HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 96. SAUDI ARABIA HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 97. UAE HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 98. UAE HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 99. UAE HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 100. ARGENTINA HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 101. ARGENTINA HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 102. ARGENTINA HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 103. REST OF LAMEA HCV DIRECT ACTING ANTIVIRAL, BY  PRODUCT TYPE, 2025-2033 ($MILLION)
  • TABLE 104. REST OF LAMEA HCV DIRECT ACTING ANTIVIRAL, BY DRUG CLASS, 2025-2033 ($MILLION)
  • TABLE 105. REST OF LAMEA HCV DIRECT ACTING ANTIVIRAL, BY DISTRIBUTION CHANNEL, 2025-2033 ($MILLION)
  • TABLE 106. MERCK AND CO.: KEY EXECUTIVES
  • TABLE 107. MERCK AND CO.: COMPANY SNAPSHOT
  • TABLE 108. MERCK AND CO.: OPERATING SEGMENTS
  • TABLE 109. MERCK AND CO.: PRODUCT PORTFOLIO
  • TABLE 110. MERCK AND CO.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. GENENTECH: KEY EXECUTIVES
  • TABLE 112. GENENTECH: COMPANY SNAPSHOT
  • TABLE 113. GENENTECH: OPERATING SEGMENTS
  • TABLE 114. GENENTECH: PRODUCT PORTFOLIO
  • TABLE 115. GENENTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. VERTEX: KEY EXECUTIVES
  • TABLE 117. VERTEX: COMPANY SNAPSHOT
  • TABLE 118. VERTEX: OPERATING SEGMENTS
  • TABLE 119. VERTEX: PRODUCT PORTFOLIO
  • TABLE 120. VERTEX: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 121. JOHNSON AND JOHNSON SERVICES, INC.: KEY EXECUTIVES
  • TABLE 122. JOHNSON AND JOHNSON SERVICES, INC.: COMPANY SNAPSHOT
  • TABLE 123. JOHNSON AND JOHNSON SERVICES, INC.: OPERATING SEGMENTS
  • TABLE 124. JOHNSON AND JOHNSON SERVICES, INC.: PRODUCT PORTFOLIO
  • TABLE 125. JOHNSON AND JOHNSON SERVICES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 126. F. HOFFMANN-LA ROCHE: KEY EXECUTIVES
  • TABLE 127. F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT
  • TABLE 128. F. HOFFMANN-LA ROCHE: OPERATING SEGMENTS
  • TABLE 129. F. HOFFMANN-LA ROCHE: PRODUCT PORTFOLIO
  • TABLE 130. F. HOFFMANN-LA ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 131. BRISTOL MYERS SQUIBB: KEY EXECUTIVES
  • TABLE 132. BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT
  • TABLE 133. BRISTOL MYERS SQUIBB: OPERATING SEGMENTS
  • TABLE 134. BRISTOL MYERS SQUIBB: PRODUCT PORTFOLIO
  • TABLE 135. BRISTOL MYERS SQUIBB: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 136. ABBVIE: KEY EXECUTIVES
  • TABLE 137. ABBVIE: COMPANY SNAPSHOT
  • TABLE 138. ABBVIE: OPERATING SEGMENTS
  • TABLE 139. ABBVIE: PRODUCT PORTFOLIO
  • TABLE 140. ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 141. GILEAD SCIENCES.: KEY EXECUTIVES
  • TABLE 142. GILEAD SCIENCES.: COMPANY SNAPSHOT
  • TABLE 143. GILEAD SCIENCES.: OPERATING SEGMENTS
  • TABLE 144. GILEAD SCIENCES.: PRODUCT PORTFOLIO
  • TABLE 145. GILEAD SCIENCES.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL HCV DIRECT ACTING ANTIVIRAL MARKET SEGMENTATION
  • FIGURE 2. GLOBAL HCV DIRECT ACTING ANTIVIRAL MARKET
  • FIGURE 3. SEGMENTATION HCV DIRECT ACTING ANTIVIRAL MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN HCV DIRECT ACTING ANTIVIRAL MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALHCV DIRECT ACTING ANTIVIRAL MARKET
  • FIGURE 11. HCV DIRECT ACTING ANTIVIRAL MARKET SEGMENTATION, BY BY  PRODUCT TYPE
  • FIGURE 12. HCV DIRECT ACTING ANTIVIRAL MARKET FOR HCV ANTIBODY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. HCV DIRECT ACTING ANTIVIRAL MARKET FOR HCV VIRAL LOAD, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. HCV DIRECT ACTING ANTIVIRAL MARKET FOR HCV GENOTYPING, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. HCV DIRECT ACTING ANTIVIRAL MARKET SEGMENTATION, BY BY DRUG CLASS
  • FIGURE 16. HCV DIRECT ACTING ANTIVIRAL MARKET FOR NS3/4A PROTEASE INHIBITORS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. HCV DIRECT ACTING ANTIVIRAL MARKET FOR NS5A POLYMERASE INHIBITORS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. HCV DIRECT ACTING ANTIVIRAL MARKET FOR NS5B POLYMERASE INHIBITORS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. HCV DIRECT ACTING ANTIVIRAL MARKET FOR COMBINATION DRUGS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. HCV DIRECT ACTING ANTIVIRAL MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 21. HCV DIRECT ACTING ANTIVIRAL MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. HCV DIRECT ACTING ANTIVIRAL MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 23. HCV DIRECT ACTING ANTIVIRAL MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 25. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 26. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 27. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 28. COMPETITIVE DASHBOARD
  • FIGURE 29. COMPETITIVE HEATMAP: HCV DIRECT ACTING ANTIVIRAL MARKET
  • FIGURE 30. TOP PLAYER POSITIONING, 2024
  • FIGURE 31. MERCK AND CO.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. MERCK AND CO.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. MERCK AND CO.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. GENENTECH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. GENENTECH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. GENENTECH: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. VERTEX: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. VERTEX: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. VERTEX: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. JOHNSON AND JOHNSON SERVICES, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. JOHNSON AND JOHNSON SERVICES, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. JOHNSON AND JOHNSON SERVICES, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. F. HOFFMANN-LA ROCHE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. F. HOFFMANN-LA ROCHE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. F. HOFFMANN-LA ROCHE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. BRISTOL MYERS SQUIBB: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. BRISTOL MYERS SQUIBB: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. BRISTOL MYERS SQUIBB: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. ABBVIE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. ABBVIE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. ABBVIE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. GILEAD SCIENCES.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. GILEAD SCIENCES.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. GILEAD SCIENCES.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
HCV Direct Acting Antiviral Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved